Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference
January 06 2020 - 7:00AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that management will present
a company overview at the 38th Annual J.P. Morgan Healthcare
Conference on Monday, January 13, 2020 at 10:30 am PT (1:30 pm ET)
at The Westin St. Francis in San Francisco. This presentation will
include an update on unaudited fourth quarter and full year 2019
global net product revenues. In addition, the Company will webcast
the Q&A breakout session immediately following its presentation
at 11:00 am PT (2:00 pm ET).
A live audio webcast of both the presentation and breakout
session will be available on the Investors section of the Company’s
website, www.alnylam.com. A replay will be available on the Alnylam
website within 48 hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of people afflicted with
rare genetic, cardio-metabolic, hepatic infectious, and central
nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning
science, RNAi therapeutics represent a powerful, clinically
validated approach for the treatment of a wide range of severe and
debilitating diseases. Founded in 2002, Alnylam is delivering on a
bold vision to turn scientific possibility into reality, with a
robust discovery platform. Alnylam’s commercial RNAi therapeutic
products are ONPATTRO® (patisiran), approved in the U.S., EU,
Canada, Japan, and Switzerland, and GIVLAARI™ (givosiran), approved
in the U.S. Alnylam has a deep pipeline of investigational
medicines, including five product candidates that are in late-stage
development. Looking forward, Alnylam will continue to execute on
its “Alnylam 2020” strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable
pipeline of RNAi-based medicines to address the needs of patients
who have limited or inadequate treatment options. Alnylam employs
over 1,200 people worldwide and is headquartered in Cambridge, MA.
For more information about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at @Alnylam or
on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200106005349/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors) 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2024 to May 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From May 2023 to May 2024